The logic of using a downstream inhibitor to block the consequences of an otherwise undruggable upstream gene defect is thus supported, reinforcing lessons learned from constitutive KRAS-mutant-activated colorectal cancer in which upstream RAS-ERK blockade by EGFR antibodies is ineffective (54). This evidence concerns the gene KRAS and colorectal cancer.